Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC): Final overall survival (OS) results. - Sternberg,C.N.; Hawkins,R.E.; Szczylik,C. (Ann Oncol, 2010)